BIIB Biogen Inc
Price (delayed)
$140.64
Market cap
$20.59B
P/E Ratio
12.55
Dividend/share
N/A
EPS
$11.21
Enterprise value
$24.84B
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Highlights
The P/E is 42% below the last 4 quarters average of 21.7 and 31% below the 5-year quarterly average of 18.2
Biogen's net income has increased by 41% YoY
The company's quick ratio fell by 16% YoY but it rose by 13% QoQ
Key stats
What are the main financial stats of BIIB
Market
Valuations
Earnings
Shares outstanding
146.37M
Market cap
$20.59B
Enterprise value
$24.84B
Price to earnings (P/E)
12.55
Price to book (P/B)
1.23
Price to sales (P/S)
2.12
EV/EBIT
13.03
EV/EBITDA
9.41
EV/Sales
2.57
Revenue
$9.68B
Gross profit
$7.37B
Operating income
$1.91B
Net income
$1.63B
EBIT
$1.91B
EBITDA
$2.64B
Free cash flow
$2.6B
Per share
Balance sheet
Liquidity
EPS
$11.21
EPS diluted
$11.18
Free cash flow per share
$17.89
Book value per share
$114.71
Revenue per share
$66.46
TBVPS
$81.59
Total assets
$28.05B
Total liabilities
$11.33B
Debt
$6.63B
Equity
$16.72B
Working capital
$1.93B
Debt to equity
0.4
Current ratio
1.35
Quick ratio
0.77
Net debt/EBITDA
1.61
Margins
Efficiency
Dividend
EBITDA margin
27.3%
Gross margin
76.1%
Net margin
16.9%
Operating margin
19.7%
Return on assets
5.9%
Return on equity
10.2%
Return on invested capital
15%
Return on capital employed
8.5%
Return on sales
19.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIIB stock price
How has the Biogen stock price performed over time
Intraday
2.6%
1 week
2.41%
1 month
-0.24%
1 year
-36.39%
YTD
-8.03%
QTD
-8.03%
Financial performance
How have Biogen's revenue and profit performed over time
Revenue
$9.68B
Gross profit
$7.37B
Operating income
$1.91B
Net income
$1.63B
Gross margin
76.1%
Net margin
16.9%
Biogen's operating margin has increased by 49% YoY
BIIB's operating income is up by 47% year-on-year
Biogen's net margin has increased by 43% YoY
Biogen's net income has increased by 41% YoY
Growth
What is Biogen's growth rate over time
Valuation
What is Biogen stock price valuation
P/E
12.55
P/B
1.23
P/S
2.12
EV/EBIT
13.03
EV/EBITDA
9.41
EV/Sales
2.57
The P/E is 42% below the last 4 quarters average of 21.7 and 31% below the 5-year quarterly average of 18.2
The EPS has grown by 40% YoY
BIIB's price to book (P/B) is 60% lower than its 5-year quarterly average of 3.1 and 32% lower than its last 4 quarters average of 1.8
The equity has grown by 13% YoY and by 2.2% from the previous quarter
The stock's price to sales (P/S) is 38% less than its 5-year quarterly average of 3.4 and 29% less than its last 4 quarters average of 3.0
Efficiency
How efficient is Biogen business performance
The ROIC has soared by 90% YoY and by 9% from the previous quarter
The ROS has grown by 49% YoY
Biogen's return on assets has increased by 34% YoY
The ROE has grown by 26% YoY
Dividends
What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIIB.
Financial health
How did Biogen financials performed over time
The total assets is 147% more than the total liabilities
The current ratio has contracted by 33% YoY but it has grown by 7% from the previous quarter
The company's quick ratio fell by 16% YoY but it rose by 13% QoQ
Biogen's debt is 60% less than its equity
The debt to equity has decreased by 20% YoY and by 2.4% from the previous quarter
The equity has grown by 13% YoY and by 2.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.